Opportunity
SAM #FDA-75F40126Q00143
FDA Acquisition of Progenesis QI Software Perpetual License for Laboratory Data Analysis
Buyer
FDA Office of the Associate General Counsel for Administrative Law
Posted
May 14, 2026
Respond By
May 25, 2026
Identifier
FDA-75F40126Q00143
NAICS
5132, 511210
The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), is seeking to acquire a perpetual software license for advanced laboratory data analysis. - Government Buyer: - Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Quality (OPQ), Office of Pharmaceutical Quality Research (OPQR) - OEM Highlight: - Progenesis QI Software is the only specified OEM - Products/Services Requested: - One (1) commercial perpetual software license for Progenesis QI Software - Supports vendor-neutral LC-MS data analysis for peptide workflows and regulatory science - Must be compatible with Windows 11 - One (1) license key/activation credentials - One (1) set of user documentation/manuals - Notable Requirements: - Delivery of all items within 90 calendar days of award - Updates applicable to the licensed version must be provided during the one-year contract period - No system development, hosting, or ongoing managed services are included - Place of Performance/Delivery: - FDA/CDER/OPQ/OPQR, 645 S Newstead Ave., St. Louis, MO 63110
Description
Contractor shall provide one (1) commercial perpetual software license for Progenesis QI Software License. The scope includes delivery of the software, activation credentials, and applicable commercial documentation. This acquisition does not include system development, hosting services, contractor access to FDA systems, or ongoing managed services.